Y Intercept Hong Kong Ltd Increases Stock Holdings in Zoetis Inc. $ZTS

Y Intercept Hong Kong Ltd increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 43.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 84,902 shares of the company’s stock after buying an additional 25,889 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Zoetis were worth $12,423,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. REAP Financial Group LLC grew its holdings in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the period. NewSquare Capital LLC increased its position in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. ORG Partners LLC increased its position in Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after purchasing an additional 84 shares during the last quarter. Finally, Financial Consulate Inc. purchased a new position in Zoetis during the third quarter worth approximately $39,000. 92.80% of the stock is owned by institutional investors and hedge funds.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Seeking Alpha publishes a contrarian bullish take calling Zoetis “undervalued and oversold,” arguing the recent pullback creates a buying opportunity for long-term investors. Zoetis: Undervalued And Oversold
• Positive Sentiment: Wall Street Zen upgraded ZTS to a “Buy,” providing short-term bullish analyst support that can attract investors looking for rebound trades. Zoetis (NYSE:ZTS) Upgraded by Wall Street Zen to “Buy” Rating
• Positive Sentiment: Zacks and other research note Zoetis’ strong earnings-surprise history and flag a reasonable chance the company could beat upcoming estimates — a potential catalyst to re-rate the stock higher if results impress. Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Coverage noting a roughly 24% one‑year pullback frames ZTS as a value/opportunity trade for investors focused on long-term fundamentals and steady margins. Is Zoetis (ZTS) Offering An Opportunity After A 24% One-Year Share Price Pullback
• Neutral Sentiment: Analyst consensus remains middling: an aggregate “Hold”/average recommendation that signals neither broad optimism nor widespread pessimism from the Street. Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: Benzinga’s roundup of eight analyst notes highlights mixed views and varied price targets — useful context but not a single decisive catalyst. 7ZTS : What 8 Analyst Ratings Have To Say About Zoetis
• Negative Sentiment: Piper Sandler downgraded ZTS from Overweight to Neutral and cut its price target from $190 to $135 — a material reduction in upside that likely pressured the stock and sentiment. Piper Sandler Downgrades Zoetis to Neutral (StreetInsider)

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research note on Thursday, December 18th. HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday. KeyCorp initiated coverage on Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Trading Down 0.3%

Shares of ZTS opened at $124.04 on Friday. The stock’s 50-day moving average is $123.58 and its two-hundred day moving average is $138.43. The stock has a market cap of $54.66 billion, a PE ratio of 20.88, a P/E/G ratio of 2.16 and a beta of 0.97. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 20th. Zoetis’s payout ratio is 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.